Search Result

Results for "

Anti-tumor Efficacy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Akt (2) Amyloid-β (2) Androgen Receptor (1) Antibiotic (3) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (29) Autophagy (5) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (1) Btk (1) c-Fms (1) c-Kit (3) c-Met/HGFR (2) Caspase (2) CDK (3) Cholinesterase (ChE) (1) Deubiquitinase (1) Discoidin Domain Receptor (2) DNA/RNA Synthesis (3) Drug-Linker Conjugates for ADC (2) DYRK (2) EGFR (7) Endogenous Metabolite (3) Epigenetic Reader Domain (1) ERK (3) Estrogen Receptor/ERR (4) Ferroptosis (1) FGFR (5) FLT3 (4) Fungal (2) GLP Receptor (1) HDAC (10) Histone Acetyltransferase (1) Histone Demethylase (1) Histone Methyltransferase (2) HIV (4) HSP (1) IKK (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Isotope-Labeled Compounds (1) Itk (1) JAK (1) JNK (1) Kinesin (1) Lipoxygenase (1) MAP4K (2) MDM-2/p53 (1) MEK (1) Microtubule/Tubulin (6) Mitochondrial Metabolism (3) Monoamine Oxidase (1) NAMPT (1) Necroptosis (1) NF-κB (4) NOD-like Receptor (NLR) (1) P-glycoprotein (2) PAK (1) PARP (2) PD-1/PD-L1 (1) PDGFR (1) Phosphatase (1) PI3K (2) PI4K (1) Pim (1) PROTACs (6) Proteasome (1) Raf (2) Ras (2) Reactive Oxygen Species (1) RET (1) SHP2 (1) STING (5) TAM Receptor (2) Tim3 (1) Toll-like Receptor (TLR) (1) Topoisomerase (2) Trk Receptor (4) VEGFR (10) YAP (1)
By Research Areas:	Cancer (118) Cardiovascular Disease (1) Infection (7) Inflammation/Immunology (13) Neurological Disease (1)
Click Chemistry:	Alkynes (2)

121

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150256

YTP-17

YAP Cancer

YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC₅₀ of 4 nM. YTP-17 shows anti-tumor efficacy .

YTP-17	YAP	Cancer
YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC₅₀ of 4 nM. YTP-17 shows anti-tumor efficacy .

HY-15496

E6201 ER-806201	MEK FLT3	Cancer
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy .

HY-157302

c-Met-IN-21

c-Met/HGFR Cancer

c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

c-Met-IN-21	c-Met/HGFR	Cancer
c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

HY-155146

Anticancer agent 146	Necroptosis	Cancer
Anticancer agent 146 (compound 1.19) is a necroptosis inducer. Anticancer agent 146 has anti-tumor efficacy in the mouse MDA-MB-231 xenograft model .

HY-13646C

Encequidar mesylate hydrochloride HM30181 mesylate hydrochloride; HM30181A mesylate hydrochloride	P-glycoprotein	Cancer
Encequidar (HM30181) mesylate hydrochloride is a potent and selective inhibitor of P-glycoprotein (MDR1). Encequidar mesylate hydrochloride improves anti-tumor efficacy of Paclitaxel (HY-B0015) in mouse tumor models .

HY-130116A

IACS-8779 disodium	STING	Cancer
IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .

HY-130628

PAK4-IN-1	PAK	Cancer
PAK4-IN-1 (Compound 19) is a potent, selective, orally active PAK4 inhibitor with robust anti-tumor efficacy in vivo. PAK4-IN-1 is stable under both acidic and neutral conditions .

HY-111458

GSK2643943A 3 Publications Verification	Deubiquitinase	Cancer
GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC₅₀ of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Others	Others
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-157029S

KRASG12D-IN-1	Ras	Cancer
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2	Ras	Cancer
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-115400

1V209 2 Publications Verification TLR7 agonist T7	Toll-like Receptor (TLR)	Cancer
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity .

HY-119272

EF24	ERK Caspase	Cancer
EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .

HY-13659

KRN5500 NSC 650426	Antibiotic Bcl-2 Family Apoptosis	Infection Cancer
KRN5500 (NSC 650426), a Spicamycin (HY-127130) derivative and a nucleoside-like antibiotic with anti-tumor activity. KRN5500 also induces apoptosis via the down-regulation of Bcl-2 expression. KRN5500 shows a significant efficacy in the human tumor xenograft model in mice .

HY-155681

SWS1	PD-1/PD-L1 Monoamine Oxidase	Cancer
SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC₅₀: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%) .

HY-115581

Thymidine 3',5'-disphosphate Deoxythymidine 3′,5′-diphosphate; pdTp	Apoptosis	Cancer
Thymidine 3',5'-disphosphate (Deoxythymidine 3′,5′-diphosphate; pdTp) is a selective small molecule inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the miRNA regulatory complex RISC subunit) and inhibits SND1 activity. Thymidine 3',5'-disphosphate exhibits anti-tumor efficacy in vivo .

HY-115567

5-NIdR 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole	Apoptosis	Cancer
5-NIdR (1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole), an artificial nucleoside, exhibits the ability to inhibit the replication of DNA lesions generated by Temozolomide (HY-17364). 5-NIdR induces cancer cells apoptosis and arrests cell cycle at G0 phase. 5-NIdR enhances Temozolomide anti-tumor efficacy in murine glioblastoma model .

HY-149428

AD4 1 Publications Verification	PROTACs	Cancer
AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC₅₀: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .

HY-155995

PRO-905 MK-905	Others	Cancer
Pro-905 is a phosphite peptide with antitumor activity. Pro-905 delivers the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to the tumor. Pro-905 effectively prevents incorporation of purine salvage substrates into nucleic acids and inhibits colony formation in human malignant peripheral nerve sheath tumors (MPNST) cells. Pro-905 inhibits purine salvage incorporation to nucleic acids and prevents cell growth. Pro-905 inhibits the growth of MPNST and enhances the anti-tumor efficacy of JHU395 (HY-124778) .

HY-121349

Aerothionin	Bacterial Fungal Antibiotic	Infection Cancer
Aerothionin is an antibiotic with potent antimicrobial efficacy against bacteria and fungi. Aerothionin exhibits antitumor efficacy against adrenal pheochromocytomas and extra-adrenal paragangliomas (PPGLs) .

HY-156249

NMS-P528

ADC Cytotoxin Cancer

NMS-P528 is a Duocarmycin derivative that can be used as an ADC payload. NMS-P528 can be used to synthesize NMS-P945 .

NMS-P528	ADC Cytotoxin	Cancer
NMS-P528 is a Duocarmycin derivative that can be used as an ADC payload. NMS-P528 can be used to synthesize NMS-P945 .

HY-151443

HDAC-IN-47	HDAC	Cancer
HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC₅₀s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo .

HY-130115

IACS-8803

STING Cancer

IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .

IACS-8803	STING	Cancer
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .

HY-149539

PLM-101	FLT3 RET	Cancer
PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) .

HY-130116

IACS-8779

STING Cancer

IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy .
HY-161077

QP5020

Amyloid-β Cancer

QP5020 (compound 28) is an inhibitor of QPCTL with an IC ⁵⁰ value of 15 nM. QP5020 has antitumor efficacy .
HY-161078

QP5038

Amyloid-β Cancer

QP5038 (compound 28) is an inhibitor of QPCTL with an IC₅₀ value of 3.8 nM. QP5038 has antitumor efficacy .
HY-162449

GIC-20

Apoptosis Ferroptosis Cancer

GIC-20 is a dual inducer for apoptosis and ferroptosis. GIC-20 exhibits antitumor efficacy against fibrosarcoma .

IACS-8779	STING	Cancer
IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy .

QP5020	Amyloid-β	Cancer
QP5020 (compound 28) is an inhibitor of QPCTL with an IC ⁵⁰ value of 15 nM. QP5020 has *antitumor* efficacy .

QP5038	Amyloid-β	Cancer
QP5038 (compound 28) is an inhibitor of QPCTL with an IC₅₀ value of 3.8 nM. QP5038 has *antitumor* efficacy .

GIC-20	Apoptosis Ferroptosis	Cancer
GIC-20 is a dual inducer for apoptosis and ferroptosis. GIC-20 exhibits antitumor efficacy against fibrosarcoma .

HY-158156

NF-κB-IN-16	NF-κB	Cancer
NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, generate reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models.

HY-N1934

Dihydroberberine
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-130115A

IACS-8803 disodium

STING Cancer

IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .
HY-130115B

IACS-8803 diammonium

STING Cancer

IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy .

IACS-8803 disodium	STING	Cancer
IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .

IACS-8803 diammonium	STING	Cancer
IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy .

HY-155020

Antitumor agent-101	Histone Methyltransferase GLP Receptor	Cancer
Antitumor agent-101 is a selective covalent inhibitor of lysine methyltransferases G9a/GLP, with IC₅₀s of 8.5 nM and 5.5 nM for G9a and GLP, respectively. Antitumor agent-101 shows antitumor efficacy in the PANC-1 xenograft model .

HY-100510

RAF709 5+ Cited Publications	Raf	Cancer
RAF709 is a potent, selective, and efficacious RAF inhibitor with IC₅₀s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively . Antitumor efficacy .

HY-133117A

(Rac)-BAY-985

IKK Cancer

(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective TBK1 inhibitor with an IC₅₀ of 1.5 nM. Antitumor efficacy .

(Rac)-BAY-985	IKK	Cancer
(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective TBK1 inhibitor with an IC₅₀ of 1.5 nM. Antitumor efficacy .

HY-155647

Microtubule stabilizing agent-1	Microtubule/Tubulin	Cancer
Microtubule stabilizing agent-1 (compound 3l) is a Paclitaxel derivative that efficiently promotes tubulin polymerization. Microtubule stabilizing agent-1 shows antitumor efficacy .

HY-162085

Axl-IN-17

TAM Receptor Cancer

Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .

Axl-IN-17	TAM Receptor	Cancer
Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .

HY-138799A

KA2507 monohydrochloride	HDAC	Inflammation/Immunology Cancer
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC₅₀=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects .

HY-147136

MYF-03-176	Others	Cancer
MYF-03-176 is an orally active and potent anticancer agent. MYF-03-176 shows strong antitumor efficacy in MPM mouse xenograft model via oral administration .

HY-146231

SS47	PROTACs MAP4K	Inflammation/Immunology Cancer
SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy .

HY-13636S

Fulvestrant-d3 ICI 182780-d₃; ZD 9238-d₃; ZM 182780-d₃	Isotope-Labeled Compounds Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].

HY-145688

HDAC-IN-33	HDAC	Cancer
HDAC-IN-33 is a potent HDAC inhibitor with IC₅₀s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-146465

Anticancer agent 60	Microtubule/Tubulin	Cancer
Anticancer agent 60 (compound 3h) has antiproliferative activity against human HepG2 cells (IC₅₀ = 4.13 μM) and presents antitumor efficacy in a human HepG2 xenograft mouse model .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-149717

Antitumor agent-122	Others	Cancer
Antitumor agent-122 (Compound 5j) is an antitumor agent with good efficacy, limited toxicity and low resistance. Antitumor agent-122 has antiproliferative activity for MGC-803 cell, HepG2 cell, SKOV3 cell and T24 cell with IC₅₀ values of 5.23 μM, 3.60 μM, 1.43 μM, 3.03 μM, respectively .

HY-145687

HDAC-IN-32	HDAC	Cancer
HDAC-IN-32 is a potent HDAC inhibitor with IC₅₀s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-151292

Antitumor agent-74	DNA/RNA Synthesis	Cancer
Antitumor agent-74 (compound 13da) is a quinoxalines derivative, an antitumor agent. Antitumor agent-74 exhibits more potent efficacy on tumor inhibition, mixed with regioisomer Antitumor agent-75 (HY-151295, compound 14 da) (mriBIQ 13da/14da). mriBIQ 13da/14da attests cell cycle at S phase, inhibits DNA synthesis, and induces mithochondrial apoptosis .

HY-N8342

Rhamnazin	VEGFR	Inflammation/Immunology Cancer
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-101144

RSM-932A TCD-717	Others	Cancer
RSM-932A (TCD-717) is a specific ChoKα inhibitor with IC₅₀s of 1 and 33 μM for human recombinant ChoKα and ChoKβ enzymes, respectively. RSM-932A acts as the “first in humans” compound targeting ChoKα. RSM-932A is potent in vitro anti-proliferative and in vivo anti-tumoral activity against human xenografts in mice, showing high efficacy with low toxicity profiles .

HY-139782

SKLB325	Histone Demethylase Apoptosis	Cancer
SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (K_D) value of 0.755 μM, and the IC₅₀ value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis . SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Structural Classification Classification of Application Fields Animals Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Others
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-N6693

Valinomycin 3 Publications Verification NSC 122023	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Apoptosis Antibiotic Autophagy Fungal
Valinomycin is a potassium-specific ionophore, the valinomycin-K ⁺ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K ⁺ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .

HY-N0492

α-Lipoic Acid 5 Publications Verification Thioctic acid; (±)-α-Lipoic acid; DL-α-Lipoic acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	NF-κB HIV Mitochondrial Metabolism Endogenous Metabolite Apoptosis
α-Lipoic Acid (Thioctic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation . α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells . α-Lipoic Acid can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1 .

HY-121349

Aerothionin	Structural Classification Antibiotics Marine natural products Source classification Sponge	Bacterial Fungal Antibiotic
Aerothionin is an antibiotic with potent antimicrobial efficacy against bacteria and fungi. Aerothionin exhibits antitumor efficacy against adrenal pheochromocytomas and extra-adrenal paragangliomas (PPGLs) .

HY-N8342

Rhamnazin	Structural Classification Combretaceae Source classification Phenols Polyphenols Plants Combretum erythrophyllum Sond.	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-N0492A

α-Lipoic Acid sodium Thioctic acid sodium; (±)-α-Lipoic acid sodium; DL-α-Lipoic acid sodium	Infection Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	NF-κB HIV Mitochondrial Metabolism Endogenous Metabolite Apoptosis
α-Lipoic Acid (Thioctic acid) sodium is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid sodium inhibits NF-κB-dependent HIV-1 LTR activation . α-Lipoic Acid sodium induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells . α-Lipoic Acid sodium can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1 .

HY-N0492R

α-Lipoic Acid (Standard) 5 Publications Verification Thioctic acid (Standard); (±)-α-Lipoic acid (Standard); DL-α-Lipoic acid (Standard)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	NF-κB HIV Mitochondrial Metabolism Endogenous Metabolite Apoptosis
α-Lipoic Acid (Standard) is the analytical standard of α-Lipoic Acid. This product is intended for research and analytical applications. α-Lipoic Acid (Thioctic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation . α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells . α-Lipoic Acid can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1 .

HY-108052

Delphinidin 3-glucoside chloride Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride	Malvaceae Structural Classification Anthocyans Flavonoids Microorganisms Classification of Application Fields Hibiscus sabdariffa Linn. Source classification Plants Disease Research Fields Cancer	EGFR Apoptosis Akt
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC₅₀ of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC₅₀ of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

Cat. No.	Product Name	Chemical Structure

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-13636S

Fulvestrant-d3
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Anti-tumor Efficacy

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products